Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$5.63 +1.8%	$4.66	$1.58 ▼ $5.98	$492.20M	0.89	1.32 million shs	3.13 million shs
KYTX Kyverna Therapeutics	$3.82 -13.0%	$2.86	$1.78 ▼ $11.40	$189.95M	2.95	387,091 shs	462,640 shs
PGEN Precigen	$1.85 -5.1%	$1.48	$0.65 ▼ $2.17	$575.60M	1.78	1.47 million shs	1.57 million shs
SIGA Siga Technologies	$6.70 -2.3%	$6.26	$4.95 ▼ $12.83	$490.09M	0.94	713,138 shs	256,986 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	+1.81%	+8.48%	+8.27%	+86.42%	+218.98%
KYTX Kyverna Therapeutics	-12.98%	+35.46%	+18.63%	+108.74%	-61.45%
PGEN Precigen	-5.13%	+8.82%	+21.71%	+35.04%	+12.46%
SIGA Siga Technologies	-2.33%	-1.03%	+5.35%	+13.18%	-26.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATYR aTyr Pharma	2.0517 of 5 stars	3.6	1.0	0.0	2.1	1.7	0.6
KYTX Kyverna Therapeutics	1.9944 of 5 stars	3.6	2.0	0.0	2.6	0.0	0.6
PGEN Precigen	4.0459 of 5 stars	3.5	0.0	4.7	4.0	1.7	0.6
SIGA Siga Technologies	2.2192 of 5 stars	0.0	3.0	0.0	2.0	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	3.14	Buy	$20.20	258.79% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	384.29% Upside
PGEN Precigen	3.00	Buy	$6.00	224.32% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KYTX, PGEN, SIGA, and ATYR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/19/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/15/2025	PGEN Precigen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$230K	2,178.57	N/A	N/A	$0.83 per share	6.78
KYTX Kyverna Therapeutics	$7.03M	23.49	N/A	N/A	$6.17 per share	0.62
PGEN Precigen	$3.92M	139.31	N/A	N/A	$0.13 per share	14.23
SIGA Siga Technologies	$138.72M	3.45	$0.82 per share	8.20	$3.02 per share	2.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$64.02M	-$0.81	N/A	N/A	N/A	N/A	-87.09%	-64.77%	8/12/2025 (Estimated)
KYTX Kyverna Therapeutics	-$127.48M	-$3.38	N/A	N/A	N/A	N/A	-51.66%	-45.92%	8/11/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$0.67	10.00	5.36	N/A	40.30%	25.21%	22.05%	7/30/2025 (Estimated)

Latest KYTX, PGEN, SIGA, and ATYR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	PGEN Precigen	-$0.14	N/A	N/A	N/A	$0.67 million	N/A
8/12/2025	Q2 2025	ATYR aTyr Pharma	-$0.18	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	KYTX Kyverna Therapeutics	-$1.00	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
5/8/2025	Q1 2025	SIGA Siga Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million
5/7/2025	Q1 2025	ATYR aTyr Pharma	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	0.01	7.79	7.79
KYTX Kyverna Therapeutics	N/A	7.44	7.44
PGEN Precigen	N/A	3.53	3.53
SIGA Siga Technologies	N/A	8.40	6.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
KYTX Kyverna Therapeutics	18.08%
PGEN Precigen	33.51%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	3.70%
KYTX Kyverna Therapeutics	N/A
PGEN Precigen	47.10%
SIGA Siga Technologies	1.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	89.00 million	85.71 million	Optionable
KYTX Kyverna Therapeutics	96	43.22 million	N/A	Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable
SIGA Siga Technologies	40	71.44 million	70.05 million	Optionable

KYTX, PGEN, SIGA, and ATYR Headlines

Recent News About These Companies

Siga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should Know

July 15 at 12:06 AM | msn.com

US Market's Undiscovered Gems Featuring Three Promising Small Caps

July 15 at 7:04 PM | finance.yahoo.com

Investors Purchase High Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

July 10, 2025 | americanbankingnews.com

Siga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)

July 10, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Laps the Stock Market: Here's Why

July 9, 2025 | zacks.com

SIGA Technologies Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

Why Siga Technologies Inc. (SIGA) Outpaced the Stock Market Today

June 26, 2025 | zacks.com

Investors Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

June 26, 2025 | marketbeat.com

New nuclear fuel cladding survive 3,452°F, 6 times hotter than normal reactors

June 25, 2025 | msn.com

General Atomics Achieves Another Milestone in Silicon Carbide Composite Nuclear Fuel Rod Technology

June 24, 2025 | indystar.comI

Here's Why Siga Technologies Inc. (SIGA) Fell More Than Broader Market

June 20, 2025 | zacks.com

Undiscovered Gems In US Market Including SIGA Technologies And 2 Other Small Caps

June 17, 2025 | finance.yahoo.com

Bank of America Corp DE Sells 367,682 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)

June 16, 2025 | marketbeat.com

Why Siga Technologies Inc. (SIGA) Dipped More Than Broader Market Today

June 13, 2025 | zacks.com

We Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster Earnings

May 16, 2025 | finance.yahoo.com

Undiscovered Gems in the US Market for May 2025

May 15, 2025 | finance.yahoo.com

SIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)

May 10, 2025 | finance.yahoo.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2025 Earnings Call Transcript

May 9, 2025 | msn.com

SIGA Reports Financial Results for Three Months Ended March 31, 2025

May 8, 2025 | globenewswire.com

Calculating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)

May 2, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for Investors

May 1, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX, PGEN, SIGA, and ATYR Company Descriptions

aTyr Pharma NASDAQ:ATYR

$5.63 +0.10 (+1.81%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$5.68 +0.05 (+0.89%)

As of 09:06 AM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Kyverna Therapeutics NASDAQ:KYTX

$3.82 -0.57 (-12.98%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$3.87 +0.05 (+1.31%)

As of 08:17 AM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Precigen NASDAQ:PGEN

$1.85 -0.10 (-5.13%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$1.90 +0.04 (+2.43%)

As of 08:07 AM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Siga Technologies NASDAQ:SIGA

$6.70 -0.16 (-2.33%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$6.70 0.00 (-0.06%)

As of 08:46 AM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time